BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29714125)

  • 1. Multivariate analysis for coronary heart disease in heterozygote familial hypercholesterolemia patients.
    Sánchez Muñoz-Torrero JF; Rivas MD; Zamorano J; Joya-Vázquez PP; de Isla LP; Padro T; Mata P; The Safeheart Investigators
    Per Med; 2018 Mar; 15(2):87-92. PubMed ID: 29714125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
    Vishwanath R; Hemphill LC
    J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early coronary calcifications are related to cholesterol burden in heterozygous familial hypercholesterolemia.
    Gallo A; Giral P; Carrié A; Carreau V; Béliard S; Bittar R; Maranghi M; Arca M; Cluzel P; Redheuil A; Bruckert E; Rosenbaum D
    J Clin Lipidol; 2017; 11(3):704-711.e2. PubMed ID: 28456681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in phenotype, genotype and cardiovascular events between patients with probable and definite heterozygous familial hypercholesterolemia.
    Cao YX; Zhou BY; Sun D; Li S; Guo YL; Zhu CG; Wu NQ; Gao Y; Xu RX; Liu G; Dong Q; Li JJ
    Per Med; 2019 Nov; 16(6):467-478. PubMed ID: 31691639
    [No Abstract]   [Full Text] [Related]  

  • 5. Value of the Definition of Severe Familial Hypercholesterolemia for Stratification of Heterozygous Patients.
    Pérez-Calahorra S; Sánchez-Hernández RM; Plana N; Marco-Benedi V; Pedro-Botet J; Almagro F; Brea A; Ascaso JF; Lahoz C; Civeira F;
    Am J Cardiol; 2017 Mar; 119(5):742-748. PubMed ID: 28081939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers.
    Besseling J; Kindt I; Hof M; Kastelein JJ; Hutten BA; Hovingh GK
    Atherosclerosis; 2014 Mar; 233(1):219-23. PubMed ID: 24529147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coronary computed tomographic angiographic findings in asymptomatic patients with heterozygous familial hypercholesterolemia and null allele low-density lipoprotein receptor mutations.
    Viladés Medel D; Leta Petracca R; Carreras Costa F; Cardona Olle M; Barros Membrilla A; Hidalgo Perez JA; Pujadas Olano S; Alomar Serrallach X; Franco Peral M; Pons-Lladó G
    Am J Cardiol; 2013 Apr; 111(7):955-61. PubMed ID: 23340035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PHACTR1 genotype predicts coronary artery disease in patients with familial hypercholesterolemia.
    Paquette M; Dufour R; Baass A
    J Clin Lipidol; 2018; 12(4):966-971. PubMed ID: 29784573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of heterozygous familial hypercholesterolemia and combined hyperlipidemia phenotype in very young survivors of myocardial infarction and their association with the severity of atheromatous burden.
    Rallidis LS; Kosmas N; Tsirebolos G; Rallidi M; Kiouri E; Kalpakos D
    J Clin Lipidol; 2019; 13(3):502-508. PubMed ID: 30956097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia.
    Kataoka Y; Harada-Shiba M; Nakao K; Nakashima T; Kawakami S; Fujino M; Kanaya T; Nagai T; Tahara Y; Asaumi Y; Hori M; Ogura M; Goto Y; Noguchi T; Yasuda S
    J Clin Lipidol; 2017; 11(2):413-421.e3. PubMed ID: 28502498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
    Arca M
    Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
    Stein EA; Dufour R; Gagne C; Gaudet D; East C; Donovan JM; Chin W; Tribble DL; McGowan M
    Circulation; 2012 Nov; 126(19):2283-92. PubMed ID: 23060426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maternally inherited hypercholesterolemia does not modify the cardiovascular phenotype in familial hypercholesterolemia.
    Marco-Benedí V; Laclaustra M; Bea AM; Suarez-Tembra M; Plana N; Pinto X; Brea A; Sanchez-Hernandez RM; Civeira F
    Atherosclerosis; 2021 Mar; 320():47-52. PubMed ID: 33529866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterozygous familial hypercholesterolemia presenting as chylomicronemia syndrome.
    Rosenson RS; Najera SD; Hegele RA
    J Clin Lipidol; 2017; 11(1):294-296. PubMed ID: 28391899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia: Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study).
    Pérez de Isla L; Alonso R; Mata N; Saltijeral A; Muñiz O; Rubio-Marin P; Diaz-Diaz JL; Fuentes F; de Andrés R; Zambón D; Galiana J; Piedecausa M; Aguado R; Mosquera D; Vidal JI; Ruiz E; Manjón L; Mauri M; Padró T; Miramontes JP; Mata P;
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):2004-10. PubMed ID: 27444203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.
    deGoma EM; Ahmad ZS; O'Brien EC; Kindt I; Shrader P; Newman CB; Pokharel Y; Baum SJ; Hemphill LC; Hudgins LC; Ahmed CD; Gidding SS; Duffy D; Neal W; Wilemon K; Roe MT; Rader DJ; Ballantyne CM; Linton MF; Duell PB; Shapiro MD; Moriarty PM; Knowles JW
    Circ Cardiovasc Genet; 2016 Jun; 9(3):240-9. PubMed ID: 27013694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two novel mutations in exon 3 and 4 of low density lipoprotein (LDL) receptor gene in patients with heterozygous familial hypercholesterolemia.
    Khan SP; Ghani R; Ahmed KZ; Yaqoob Z
    J Coll Physicians Surg Pak; 2011 Jul; 21(7):403-6. PubMed ID: 21777527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
    Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD
    J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A frequent variant in the ABCA1 gene is associated with increased coronary heart disease risk and a better response to statin treatment in familial hypercholesterolemia patients.
    Versmissen J; Oosterveer DM; Yazdanpanah M; Mulder M; Dehghan A; Defesche JC; Kastelein JJ; Sijbrands EJ
    Eur Heart J; 2011 Feb; 32(4):469-75. PubMed ID: 20595220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterozygous familial hypercholesterolemia in Hong Kong Chinese. Study of 252 cases.
    Hu M; Lan W; Lam CW; Mak YT; Pang CP; Tomlinson B
    Int J Cardiol; 2013 Aug; 167(3):762-7. PubMed ID: 22464486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.